Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.

We have used a structure-based approach to design a novel series of non-nucleoside inhibitors of HIV-1 RT (NNRTIs). Detailed analysis of a wide range of crystal structures of HIV-1 RT-NNRTI complexes together with data on drug resistance mutations has identified factors important for tight binding of inhibitors and resilience to mutations. Using this approach we have designed and synthesized a novel series of quinolone NNRTIs. Crystal structure analysis of four of these compounds in complexes with HIV-1 RT confirms the predicted binding modes. Members of this quinolone series retain high activity against the important resistance mutations in RT at Tyr181Cys and Leu100Ile.

[1]  Richard T. Walker,et al.  Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. , 1996, Journal of medicinal chemistry.

[2]  R. Bambara,et al.  Mutations within the Primer Grip Region of HIV-1 Reverse Transcriptase Result in Loss of RNase H Function* , 1997, The Journal of Biological Chemistry.

[3]  L. Bacheler,et al.  Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.

[4]  U Hübscher,et al.  Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. , 1997, Journal of molecular biology.

[5]  C. Péchoux,et al.  Mutations in the Primer Grip of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Impair Proviral DNA Synthesis and Virion Maturation , 1998, Journal of Virology.

[6]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[7]  D I Stuart,et al.  Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Erik De Clercq.  Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection , 1999 .

[9]  M. J. D. Powell,et al.  Restart procedures for the conjugate gradient method , 1977, Math. Program..

[10]  A. D. Clark,et al.  Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.

[11]  R T Walker,et al.  A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. , 1989, Journal of medicinal chemistry.

[12]  R. Esnouf,et al.  A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. , 1998, AIDS research and human retroviruses.

[13]  R T Walker,et al.  Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. , 1989, Biochemical and biophysical research communications.

[14]  D I Stuart,et al.  Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. , 1999, Journal of medicinal chemistry.

[15]  E. Domingo,et al.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy , 1995, Journal of virology.

[16]  Christoph,et al.  Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication , 1993, Antimicrobial Agents and Chemotherapy.

[17]  D. Averett.  Anti-HIV compound assessment by two novel high capacity assays. , 1989, Journal of virological methods.

[18]  Robert A. Domaoal,et al.  Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. , 2004, The international journal of biochemistry & cell biology.

[19]  A. D. Clark,et al.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. D. Clark,et al.  Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. , 1998, Journal of molecular biology.

[21]  Ettore Novellino,et al.  Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. , 2002, Current pharmaceutical design.

[22]  D I Stuart,et al.  Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding* , 2000, The Journal of Biological Chemistry.

[23]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[24]  D. Stammers,et al.  A Mutation in the 3′ Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance , 2002, Journal of Virology.

[25]  S. L. Le Grice,et al.  Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. , 1996, Biochemistry.

[26]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[27]  R. Holman,et al.  Micromethod for assaying reverse transcriptase of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus , 1987, Journal of clinical microbiology.

[28]  R. Esnouf,et al.  A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. , 1998, The Journal of general virology.

[29]  P. Novák,et al.  5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile , 1994, Antimicrobial Agents and Chemotherapy.

[30]  S. L. Le Grice,et al.  Mutating the "primer grip" of p66 HIV-1 reverse transcriptase implicates tryptophan-229 in template-primer utilization. , 1994, The Journal of biological chemistry.

[31]  R. Esnouf,et al.  Crystals of HIV-1 reverse transcriptase diffracting to 2.2 A resolution. , 1994, Journal of molecular biology.

[32]  Yvonne Jones,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors , 1995, Nature Structural Biology.

[33]  Jones Ta,et al.  Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO. , 1985, Methods in enzymology.

[34]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[35]  S. Thrall,et al.  Kinetic Analysis of Four HIV-1 Reverse Transcriptase Enzymes Mutated in the Primer Grip Region of p66 , 1997, The Journal of Biological Chemistry.

[36]  R. Esnouf,et al.  Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1 , 1997, Journal of virology.

[37]  Erik De Clercq,et al.  The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection , 1998 .

[38]  R. Huber,et al.  Accurate Bond and Angle Parameters for X-ray Protein Structure Refinement , 1991 .

[39]  R. Kaiser,et al.  Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication , 1995, Antimicrobial agents and chemotherapy.

[40]  Cheng Yung-Chi,et al.  HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. , 1992 .

[41]  D. Stuart,et al.  Allosteric Inhibitors against HIV-1 Reverse Transcriptase: Design and Synthesis of MKC-442 Analogues Having an Ω-Functionalized Acyclic Structure , 1998, Antiviral chemistry & chemotherapy.

[42]  J. Balzarini,et al.  Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. , 2004, Current topics in medicinal chemistry.

[43]  M. Haine,et al.  Van Damme A. , 1986 .

[44]  D I Stuart,et al.  Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. , 2001, Journal of molecular biology.

[45]  R. Shafer,et al.  Drug resistance mutations in HIV-1. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[46]  L. Montagnier,et al.  A rapid and simple colorimetric test for the study of anti-HIV agents. , 1988, AIDS research and human retroviruses.

[47]  Hiroshi Harada,et al.  S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1 , 1998, Antimicrobial Agents and Chemotherapy.

[48]  A. Huang,et al.  Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells , 1991, Antimicrobial Agents and Chemotherapy.

[49]  R. Kirsch,et al.  In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. , 1997, Virology.

[50]  B. Larder,et al.  Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .

[51]  D. Stuart,et al.  High resolution structures of HIV-1 RT from four RT-inhibitor complexes. , 1996 .

[52]  R. Esnouf,et al.  Mutational Analysis of Tyr-318 within the Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket of Human Immunodeficiency Virus Type I Reverse Transcriptase* , 1998, The Journal of Biological Chemistry.

[53]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[54]  Christopher A. Hunter,et al.  The nature of .pi.-.pi. interactions , 1990 .

[55]  S. L. Le Grice,et al.  Mutating a conserved motif of the HIV-1 reverse transcriptase palm subdomain alters primer utilization. , 1997, Biochemistry.

[56]  R. Esnouf,et al.  Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. , 2000, Molecular pharmacology.

[57]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[58]  S. L. Le Grice,et al.  Alanine-scanning Mutations in the “Primer Grip” of p66 HIV-1 Reverse Transcriptase Result in Selective Loss of RNA Priming Activity* , 1997, The Journal of Biological Chemistry.

[59]  K A Johnson,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors , 1995, Science.

[60]  D. Bangsberg,et al.  Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. , 2004, The Journal of antimicrobial chemotherapy.

[61]  A. D. Clark,et al.  The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. , 2001, Journal of molecular biology.

[62]  D. Stuart,et al.  The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. , 1995, Structure.